Research Topics
| John A ThompsonSummaryAffiliation: University of Washington Country: USA Publications
| Collaborators
|
Detail Information
Publications
Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study GroupJ A Thompson
Division of Oncology, University of Washington, Seattle, WA 98195 6043, USA
Blood 95:1175-9. 2000..GM-CSF +/- epoetin alfa had no effect on mean platelet count. Treatment was well tolerated in most patients, though 10 withdrew from the study for reasons related predominantly to GM-CSF toxicity. (Blood. 2000;95:1175-1179)..- Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trialJohn A Thompson
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
J Immunother 35:73-7. 2012..These retrospective analyses are the first to provide survival data for ipilimumab in treatment-naive and previously treated patients within the same clinical trial... - Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II studyJohn A Thompson
Division of Medical Oncology, University of Washington, Seattle, WA, USA
Clin Genitourin Cancer 7:E58-65. 2009.... - Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinomaJohn A Thompson
Seattle Cancer Care Alliance, 825 Eastlake Ave East, Mailstop G4 830, Seattle, WA 98109 1023, USA
J Clin Oncol 26:2034-9. 2008.... - Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomizJohn A Thompson
Puget Sound Oncology Consortium, Seattle, WA, USA
Blood 111:4048-54. 2008..Posttransplantation IL-2 given at this dose and schedule of administration had no significant effect on PFS or OS. This study is registered at www.clinicaltrials.gov as NCT00002649... - A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinomaJohn A Thompson
University of Washington, Seattle, Washington 98109 1023, USA
Clin Cancer Res 9:3562-70. 2003..This study assessed the safety, immunostimulatory effects, and antitumor activity of Xcellerated T Cells and interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (RCC)... - Treatment of metastatic melanoma: an overviewShailender Bhatia
Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington 98109, USA
Oncology (Williston Park) 23:488-96. 2009..In this article, we review the treatments for metastatic melanoma including promising investigational approaches... - Metastatic renal cell carcinoma: current standards of careJohn A Thompson
School of Medicine, University of Washington, Seattle, USA
Clin J Oncol Nurs 13:8-12. 2009..This article reviews surgical options for metastatic renal cell carcinoma as well as clinical trial data on treatment strategies with cytokines and targeted agents... - Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigensScott S Tykodi
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA
Clin Cancer Res 10:7799-811. 2004..Such antigens may represent therapeutic targets for posttransplant vaccination or adoptive T-cell therapy to augment the antitumor effects of allogeneic hematopoietic cell transplantation... - Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years afterScott S Tykodi
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Expert Opin Biol Ther 11:763-73. 2011.... - Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantationNehal Masood
Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA 98109-1023, USA
J Am Acad Dermatol 47:140-5. 2002..Although the results in this patient are encouraging, more patients and longer follow-up are needed to define the usefulness of Allo SCT in the treatment of MF... - Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotypeAude G Chapuis
Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Proc Natl Acad Sci U S A 109:4592-7. 2012.... - Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1Naomi N Hunder
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
N Engl J Med 358:2698-703. 2008..We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1... - Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case reportShailender Bhatia
Department of Medical Oncology, University of Washington, Seattle, WA 98109, USA
J Immunother 32:203-5. 2009..We discuss the pathophysiology and suggest careful monitoring of patients for development of this complication from ipilimumab therapy... - Temsirolimus in patients with advanced renal cell carcinoma: an overviewShailender Bhatia
Division of Medical Oncology, Department of Medicine, University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Adv Ther 26:55-67. 2009..The status of temsirolimus in the rapidly evolving therapeutic landscape of advanced RCC is also discussed... - Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanomaHerschel Wallen
Department of Clinical Research, Fred Hutchison Cancer Research Center, Seattle, Washington, United States of America
PLoS ONE 4:e4749. 2009.... - Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancerScott S Tykodi
Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Mailstop G4 830, Seattle, WA 98109 1023, USA
Expert Opin Biol Ther 8:1947-53. 2008..A recombinant pox virus vector expressing this antigen, modified vaccinia Ankara (MVA)-5T4, has been tested as a cancer vaccine... - The revised American Joint Committee on Cancer staging system for melanomaJohn A Thompson
Seattle Cancer Care Alliance, WA 98109-1023, USA
Semin Oncol 29:361-9. 2002.... - Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteinsMichael G Dodds
Preclinical Development, ZymoGenetics, Seattle, WA 98102, USA
Cancer Immunol Immunother 58:843-54. 2009..A secondary objective of these trials was to characterize pharmacodynamic responses to rIL-21 in patients. Here, we report the effects of systemic rIL-21 on serum markers of immune stimulation... - Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cellsJames D Lord
Department of Medicine, University of Washington, Seattle, WA, USA
Dig Dis Sci 55:1396-405. 2010..However, we found no evidence of FOXP3(+) T cell depletion in any of the nine patients who developed colitis... - Systemic therapy for metastatic melanoma in 2012: dawn of a new eraShailender Bhatia
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, USA
J Natl Compr Canc Netw 10:403-12. 2012..This article reviews both the current systemic treatment options for metastatic melanoma and promising investigational approaches... - MelanomaAlan N Houghton
J Natl Compr Canc Netw 4:666-84. 2006 - Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancerEric K Rowinsky
Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Rd, 4th Floor, Zeller Building, San Antonio, TX 78229, USA
J Clin Oncol 22:3003-15. 2004.... - Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialRobert J Motzer
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Lancet 372:449-56. 2008..We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy... - Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcomeJeffrey A Sosman
Vanderbilt University, Nashville, TN, USA
J Clin Oncol 20:2067-75. 2002..HLA-A2 and HLA-C3 contributed most to this effect. Processed melanoma peptides found in Melacine may be presented by HLA-A2 and HLA-C3 and play a role in preventing relapse in vaccinated patients... - Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology GroupVernon K Sondak
University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
J Clin Oncol 20:2058-66. 2002..Future investigations of adjuvant vaccine approaches for patients with intermediate-thickness melanoma should involve larger numbers of patients and ideally should include sentinel node biopsy staging... - C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patientsScott S Tykodi
Program in Immunology, Fred Hutchinson Cancer Research Center
Clin Cancer Res 14:5260-9. 2008..Cellular and molecular characterization of antigens recognized by tumor-reactive T cells isolated from responding patients could potentially provide insight into the mechanisms of tumor regression... - Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidateAnna L Schwartz
Department of Primary Care, School of Nursing, Oregon Health and Science University, Portland, OR, USA
Oncol Nurs Forum 29:E85-90. 2002..To examine the effect of exercise and methylphenidate on fatigue, functional ability, and cognitive function in patients with melanoma... - Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyKenneth A Foon
Abgenix, Inc, Fremont, CA, USA
Int J Radiat Oncol Biol Phys 58:984-90. 2004..Therapy was generally well tolerated without statistically significant adverse events. Monoclonal antibody blockade of EGFR represents a new and exciting direction in cancer therapy... - An evidence-based staging system for cutaneous melanomaCharles M Balch
American Society of Clinical Oncology, Alexandria, VA, USA
CA Cancer J Clin 54:131-49; quiz 182-4. 2004..6) A new convention was implemented for defining clinical and pathological staging so as to take into account the new staging information gained from lymphatic mapping and sentinel node biopsy... - A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanomaKarl D Lewis
University of Colorado, Cancer Center, 1665 North Ursula St, Mail Stop F-703, Aurora, CO 80045, USA
Invest New Drugs 24:89-94. 2006..In conclusion, Apomine, at the current dose studied, failed to produce a 30% progression free survival rate at 16 weeks considered to be a meaningful benefit for further development... - Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanomaReinhard Dummer
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
J Clin Oncol 24:1188-94. 2006..This open-label, randomized study evaluated the safety, tolerability, and efficacy of subcutaneous PEG-IFNalpha-2a in patients with metastatic malignant melanoma (stage IV American Joint Committee on Cancer staging system)... - A phase II study of depsipeptide in refractory metastatic renal cell cancerWalter M Stadler
Department of Medicine, University of Chicago, IL 60637 1470, USA
Clin Genitourin Cancer 5:57-60. 2006..Therapeutic options for renal cell cancer are inadequate. Depsipeptide is a histone deacetylase inhibitor with promising preclinical and early clinical activity... - Fractionation of high molecular weight tannins in grape seed extract and identification of procyanidin B2-3,3'-di-O-gallate as a major active constituent causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cellsChapla Agarwal
Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA
Carcinogenesis 28:1478-84. 2007..Taken together, these data identify procyanidin B2-3,3'-di-O-gallate as a novel biologically active agent in GSE that should be studied in greater detail to determine its effects against PCA... - Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanomaMalcolm S Mitchell
University of California, San Diego, School of Medicine and Cancer Center, San Diego, CA, USA
J Clin Oncol 25:2078-85. 2007..To compare the overall survival (OS) of patients with resected stage III melanoma administered active specific immunotherapy and low-dose interferon alfa-2b (IFN-alpha-2b) with the OS achieved using high-dose IFN-alpha-2b... - Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026Laura F Hutchins
Division of Hematology Oncology, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Cancer 110:2269-75. 2007..Southwest Oncology Group protocol 0026 evaluated interferon alpha-2b plus thalidomide in patients with disseminated melanoma. Endpoints were 6-month progression-free survival rate, response rate, and toxicity... - Carbonyl reductase inactivation may contribute to mouse lung tumor promotion by electrophilic metabolites of butylated hydroxytoluene: protein alkylation in vivo and in vitroColin T Shearn
Department of Pharmaceutical Sciences, C238 L15, Anschutz Medical Campus, University of Colorado Denver, Box 6511, Aurora, Colorado 80045, USA
Chem Res Toxicol 21:1631-41. 2008..These data, in concert with previous evidence for the inactivation of antioxidant enzymes, provide a molecular basis to explain lung inflammation leading to tumor promotion in this two-stage model for pulmonary carcinogenesis... - New TNM melanoma staging system: linking biology and natural history to clinical outcomesCharles M Balch
Johns Hopkins Medical Institutions, Baltimore, MD, USA
Semin Surg Oncol 21:43-52. 2003....